Comparison of Two Formulations of Androxal
NCT01984398
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Bioequivalence
Interventions
DRUG:
12.5 mg Androxal Formulation A
DRUG:
12.5 mg Androxal Formulation B
DRUG:
25 mg Androxal Formulation A
DRUG:
25 mg Androxal Formulation B
Sponsor
Repros Therapeutics Inc.